144 related articles for article (PubMed ID: 35406537)
1. MALDI Mass Spectrometry Imaging-Prognostic Pathways and Metabolites for Renal Cell Carcinomas.
Erlmeier F; Sun N; Shen J; Feuchtinger A; Buck A; Prade VM; Kunzke T; Schraml P; Moch H; Autenrieth M; Weichert W; Hartmann A; Walch A
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406537
[TBL] [Abstract][Full Text] [Related]
2. Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging: Diagnostic Pathways and Metabolites for Renal Tumor Entities.
Erlmeier F; Sun N; Shen J; Feuchtinger A; Buck A; Prade VM; Kunzke T; Schraml P; Moch H; Autenrieth M; Weichert W; Hartmann A; Walch A
Oncology; 2023; 101(2):126-133. PubMed ID: 36198279
[TBL] [Abstract][Full Text] [Related]
3. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
[TBL] [Abstract][Full Text] [Related]
4. De novo discovery of metabolic heterogeneity with immunophenotype-guided imaging mass spectrometry.
Prade VM; Kunzke T; Feuchtinger A; Rohm M; Luber B; Lordick F; Buck A; Walch A
Mol Metab; 2020 Jun; 36():100953. PubMed ID: 32278304
[TBL] [Abstract][Full Text] [Related]
5. The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium.
Abu-Ghanem Y; Powles T; Capitanio U; Beisland C; Järvinen P; Stewart GD; Gudmundsson EO; Lam TB; Marconi L; Fernandéz-Pello S; Nisen H; Meijer RP; Volpe A; Ljungberg B; Klatte T; Dabestani S; Bex A
Eur Urol Oncol; 2021 Jun; 4(3):473-482. PubMed ID: 33109495
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma.
Kroeze SG; Bijenhof AM; Bosch JL; Jans JJ
Cancer Biomark; 2010; 7(6):261-8. PubMed ID: 21694464
[TBL] [Abstract][Full Text] [Related]
7. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
[TBL] [Abstract][Full Text] [Related]
8. How Suitable is Matrix-Assisted Laser Desorption/Ionization-Time-of-Flight for Metabolite Imaging from Clinical Formalin-Fixed and Paraffin-Embedded Tissue Samples in Comparison to Matrix-Assisted Laser Desorption/Ionization-Fourier Transform Ion Cyclotron Resonance Mass Spectrometry?
Buck A; Balluff B; Voss A; Langer R; Zitzelsberger H; Aichler M; Walch A
Anal Chem; 2016 May; 88(10):5281-9. PubMed ID: 27065343
[TBL] [Abstract][Full Text] [Related]
9. Distinguishing Renal Cell Carcinoma From Normal Kidney Tissue Using Mass Spectrometry Imaging Combined With Machine Learning.
Shankar V; Vijayalakshmi K; Nolley R; Sonn GA; Kao CS; Zhao H; Wen R; Eberlin LS; Tibshirani R; Zare RN; Brooks JD
JCO Precis Oncol; 2023 Jun; 7():e2200668. PubMed ID: 37285559
[TBL] [Abstract][Full Text] [Related]
10. A pan-kidney cancer study identifies subtype specific perturbations on pathways with potential drivers in renal cell carcinoma.
Zhan X; Liu Y; Yu CY; Wang TF; Zhang J; Ni D; Huang K
BMC Med Genomics; 2020 Dec; 13(Suppl 11):190. PubMed ID: 33371886
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological and survival analysis of clinically advanced papillary and chromophobe renal cell carcinoma.
Kaldany A; Paulucci DJ; Kannappan M; Beksac AT; Anastos H; Okhawere K; Sfakianos JP; Badani KK
Urol Oncol; 2019 Oct; 37(10):727-734. PubMed ID: 31174958
[TBL] [Abstract][Full Text] [Related]
12. Expression and clinical value of SALL4 in renal cell carcinomas.
Che J; Wu P; Wang G; Yao X; Zheng J; Guo C
Mol Med Rep; 2020 Aug; 22(2):819-827. PubMed ID: 32468053
[TBL] [Abstract][Full Text] [Related]
13. Analysis of CT, MRI imaging features of renal cell carcinoma with different histopathological types.
Wang X; Kong W; Wang Y; Wang Y; Chen Y; Shi Z; Liu Y
J BUON; 2021; 26(5):2053-2058. PubMed ID: 34761616
[TBL] [Abstract][Full Text] [Related]
14. Circulating and tissue IMP3 levels are correlated with poor survival in renal cell carcinoma.
Tschirdewahn S; Panic A; Püllen L; Harke NN; Hadaschik B; Riesz P; Horváth A; Szalontai J; Nyirády P; Baba HA; Reis H; Szarvas T
Int J Cancer; 2019 Jul; 145(2):531-539. PubMed ID: 30650187
[TBL] [Abstract][Full Text] [Related]
15. Identification of Protein Markers Specific for Papillary Renal Cell Carcinoma Using Imaging Mass Spectrometry.
Na CH; Hong JH; Kim WS; Shanta SR; Bang JY; Park D; Kim HK; Kim KP
Mol Cells; 2015 Jul; 38(7):624-9. PubMed ID: 26062552
[TBL] [Abstract][Full Text] [Related]
16. Somatic mutations in renal cell carcinomas from Chinese patients revealed by whole exome sequencing.
Wang J; Xi Z; Xi J; Zhang H; Li J; Xia Y; Yi Y
Cancer Cell Int; 2018; 18():159. PubMed ID: 30349421
[TBL] [Abstract][Full Text] [Related]
17. Differential Activation of NRF2 Signaling Pathway in Renal-Cell Carcinoma Caki Cell Lines.
Hitefield NL; Mackay S; Hays LE; Chen S; Oduor IO; Troyer DA; Nyalwidhe JO
Biomedicines; 2023 Mar; 11(4):. PubMed ID: 37189628
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis of uncommon renal epithelial neoplasms: performances of fluorescence in situ hybridization.
Beaumont M; Dugay F; Kammerer-Jacquet SF; Jaillard S; Cabillic F; Mathieu R; Verhoest G; Bensalah K; Rioux-Leclercq N; Belaud-Rotureau MA;
Hum Pathol; 2019 Oct; 92():81-90. PubMed ID: 31437522
[TBL] [Abstract][Full Text] [Related]
19. Imaging Mass Spectrometry Is an Accurate Tool in Differentiating Clear Cell Renal Cell Carcinoma and Chromophobe Renal Cell Carcinoma: A Proof-of-concept Study.
Lu HC; Patterson NH; Judd AM; Reyzer ML; Sehn JK
J Histochem Cytochem; 2020 Jun; 68(6):403-411. PubMed ID: 32466698
[TBL] [Abstract][Full Text] [Related]
20. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma.
Beck SD; Patel MI; Snyder ME; Kattan MW; Motzer RJ; Reuter VE; Russo P
Ann Surg Oncol; 2004 Jan; 11(1):71-7. PubMed ID: 14699037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]